Immuron

Home

Why Immuron?

The Digest

Announcements

Company Media

Capital Structure & Register

Analyst Reports

Annual Reports

Investor Presentations

NASDAQ

Investors

Corporate Governance

Corporate Directory

Corporate

Plus Jakarta Sans

Click here to read full article

Immuron’s lead oral therapy IMM‑124E is progressing rapidly through three concurrent Phase II trials targeting fatty liver disease: one in adult non‑alcoholic steatohepatitis (NASH) with 133 biopsy‑confirmed patients enrolled—exceeding the 120‑patient goal and slated for topline results in Q4 2017; another in alcoholic steatohepatitis (ASH), having randomized over half of the targeted 66 patients, with results expected in Q1 2019; and a pediatric NASH study at Emory University, where the first of 40 patients was enrolled in February 2017 and ~20% have been randomized, with results also anticipated in Q4 2017. Importantly, there are currently no approved therapies for NAFLD/NASH, highlighting the unmet need IMM‑124E aims to address through its gut‑targeted immunoglobulin approach.

Becker's ASC: Immuron’s fatty liver disease candidate advancing — 4 insights